Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
2.83B | 2.79B | 2.39B | 2.21B | 2.09B | 1.99B | Gross Profit |
1.04B | 1.02B | 820.57M | 791.46M | 783.95M | 628.39M | EBIT |
360.42M | 249.33M | 204.37M | -94.93M | 152.72M | 91.16M | EBITDA |
565.78M | 439.77M | 399.76M | 150.43M | 401.10M | 345.61M | Net Income Common Stockholders |
-13.05M | -116.89M | -83.99M | -129.99M | 10.62M | 91.06M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
405.24M | 110.55M | 93.74M | 27.80M | 248.96M | 341.38M | Total Assets |
4.39B | 3.50B | 3.47B | 3.80B | 3.94B | 4.01B | Total Debt |
3.28B | 2.59B | 2.75B | 2.85B | 2.88B | 2.94B | Net Debt |
2.87B | 2.48B | 2.66B | 2.82B | 2.63B | 2.60B | Total Liabilities |
3.99B | 3.61B | 3.45B | 3.59B | 3.57B | 3.66B | Stockholders Equity |
318.38M | -109.27M | 19.78M | 298.42M | 360.34M | 344.93M |
Cash Flow | Free Cash Flow | ||||
233.37M | 243.18M | 276.39M | -25.50M | 189.18M | 312.81M | Operating Cash Flow |
306.92M | 295.10M | 345.58M | 65.10M | 241.82M | 379.00M | Investing Cash Flow |
-61.03M | -63.00M | -69.19M | -174.31M | -194.18M | -317.55M | Financing Cash Flow |
-227.80M | -211.79M | -212.57M | -106.62M | -138.12M | 131.81M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
62 Neutral | $1.90B | ― | -18.12% | ― | 28.25% | 80.86% | |
56 Neutral | $2.39B | ― | 106.97% | ― | 13.42% | 92.50% | |
54 Neutral | $2.26B | ― | -31.51% | ― | ― | ― | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
53 Neutral | $3.13B | ― | -14.40% | ― | ― | -23.84% | |
49 Neutral | $2.78B | ― | 78.99% | ― | 10238.41% | 47.67% | |
41 Neutral | $3.01B | ― | -30.57% | ― | ― | -147.80% |
Amneal Pharmaceuticals held its 2025 Annual Meeting of Stockholders on May 6, 2025, where all proposals were approved, and all director nominees were elected. The meeting included the election of directors, approval of executive compensation, and ratification of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025. These approvals are expected to support the company’s governance and operational strategies moving forward.
Amneal Pharmaceuticals reported strong financial results for the first quarter of 2025, with net revenue reaching $695 million, a 5% increase from the previous year. The company achieved a net income of $12 million, a significant improvement from a net loss of $92 million in the same quarter of 2024, driven by higher revenue, gross profit, and the absence of a previous legal settlement charge. The company also reported an adjusted EBITDA of $170 million, reflecting a 12% increase, and affirmed its full-year 2025 financial guidance, indicating confidence in its growth trajectory and value creation for stakeholders.